HCWBHIGH SIGNALFINANCIAL10-K

HCWB's gross profit collapsed nearly entirely while the company burned through most of its cash reserves, creating acute liquidity concerns.

The virtual elimination of gross profit alongside a dramatic cash reduction to just $2.0M signals severe operational distress and potential going-concern issues. While losses narrowed meaningfully, this appears driven more by expense cuts than revenue improvement, suggesting the company may be in survival mode rather than executing a growth strategy.

Comparing 2026-03-31 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

HCWB experienced a financial crisis with gross profit essentially disappearing and cash reserves declining sharply from $4.7M to $2.0M. The company did manage to substantially reduce its net losses and cut R&D spending by 14.8%, while total liabilities decreased by 41.2%. However, the core business appears to have deteriorated significantly, with the minimal remaining cash position raising serious questions about the company's ability to continue operations without immediate financing.

FINANCIAL STATEMENT CHANGES
Gross Profit
P&L
-98.9%
$959K$11K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Net Income
P&L
+73.5%
-$30.0M-$8.0M

Net income grew 73.5% — bottom-line growth signals improving overall business health.

Current Assets
Balance Sheet
-59.9%
$5.7M$2.3M

Current assets declined 59.9% — monitor working capital adequacy and short-term liquidity.

Cash & Equivalents
Balance Sheet
-58.2%
$4.7M$2.0M

Cash declined 58.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Income
P&L
+55.4%
-$29.5M-$13.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Liabilities
Balance Sheet
-41.2%
$37.0M$21.8M

Liabilities reduced 41.2% — deleveraging improves balance sheet strength and financial flexibility.

Interest Expense
P&L
+33.9%
$631K$845K

Interest expense surged 33.9% — significant debt increase or rising rates materially impacting earnings.

Current Liabilities
Balance Sheet
-28.9%
$29.6M$21.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
-18.9%
$30.2M$24.5M

Total assets contracted 18.9% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
-14.8%
$6.4M$5.4M

R&D spending cut 14.8% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-28
ADDED
HCW BIOLOGICS and TOBI TM are trademarks of HCW Biologics Inc.
( HCW Biologics or the Company ) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation.
We have created novel compounds that represent a new class of drugs that we believe have the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia.
Among other things, we have begun commercialization of certain commercial-ready proprietary compounds for use as reagents in the production of immunotherapeutics for the treatment of infectious diseases and cancer.
We want our products to improve patients healthspan as well as their quality of life, and possibly extend longevity.
+7 more — sign up free →
REMOVED
( HCWB or the Company ) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases.
Our immunotherapeutics represent a new class of drug that we believe has the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation and in doing so, improve patients quality of life and possibly extend longevity.
While chronic inflammation is possible at any age, it is more common as we age.
The induction and retention of low-grade inflammation in an aging human body is mainly the result of the accumulation of non-proliferative but metabolically active senescent cells, which can also be caused by persistent activation of immune cells.
Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to the cause for senescence-associated diseases and conditions that diminish health span, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as indications that impact quality-of-life that are not life-threatening.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →